279 related articles for article (PubMed ID: 32156001)
1. Targeting Genome Integrity in
Miggiano R; Morrone C; Rossi F; Rizzi M
Molecules; 2020 Mar; 25(5):. PubMed ID: 32156001
[No Abstract] [Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Mycobacterial DNA Replication as a Target for Antituberculosis Drug Discovery.
Płocinska R; Korycka-Machala M; Plocinski P; Dziadek J
Curr Top Med Chem; 2017 Jun; 17(19):2129-2142. PubMed ID: 28137234
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
5. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
6. Dual-Acting Small-Molecule Inhibitors Targeting Mycobacterial DNA Replication.
Singh M; Ilic S; Tam B; Ben-Ishay Y; Sherf D; Pappo D; Akabayov B
Chemistry; 2020 Aug; 26(47):10849-10860. PubMed ID: 32485035
[TBL] [Abstract][Full Text] [Related]
7. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
8. Targeting tuberculosis: a glimpse of promising drug targets.
Arora N; Banerjee AK
Mini Rev Med Chem; 2012 Mar; 12(3):187-201. PubMed ID: 22356190
[TBL] [Abstract][Full Text] [Related]
9. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
10. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.
Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM
PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737
[TBL] [Abstract][Full Text] [Related]
11. Introduction: Novel insights into TB research and drug discovery.
Grüber G
Prog Biophys Mol Biol; 2020 May; 152():2-5. PubMed ID: 32087187
[TBL] [Abstract][Full Text] [Related]
12. Protein targets in Mycobacterium tuberculosis and their inhibitors for therapeutic implications: A narrative review.
Sreelatha S; Nagarajan U; Natarajan S
Int J Biol Macromol; 2023 Jul; 243():125022. PubMed ID: 37244342
[TBL] [Abstract][Full Text] [Related]
13. Computational biology in anti-tuberculosis drug discovery.
Murphy DJ; Brown JR
Infect Disord Drug Targets; 2009 Jun; 9(3):319-26. PubMed ID: 19519485
[TBL] [Abstract][Full Text] [Related]
14. Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants.
Jagadeb M; Rath SN; Sonawane A
J Cell Biochem; 2018 Sep; 119(9):7328-7338. PubMed ID: 29761826
[TBL] [Abstract][Full Text] [Related]
15. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.
Rajkhowa S; Deka RC
Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759
[TBL] [Abstract][Full Text] [Related]
16. The Expanding Diversity of Mycobacterium tuberculosis Drug Targets.
Wellington S; Hung DT
ACS Infect Dis; 2018 May; 4(5):696-714. PubMed ID: 29412643
[TBL] [Abstract][Full Text] [Related]
17. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
Chaudhari K; Surana S; Jain P; Patel HM
Eur J Med Chem; 2016 Nov; 124():160-185. PubMed ID: 27569197
[TBL] [Abstract][Full Text] [Related]
18. Importance of differential identification of Mycobacterium tuberculosis strains for understanding differences in their prevalence, treatment efficacy, and vaccine development.
Chae H; Shin SJ
J Microbiol; 2018 May; 56(5):300-311. PubMed ID: 29721826
[TBL] [Abstract][Full Text] [Related]
19. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
20. Data Intensive Genome Level Analysis for Identifying Novel, Non-Toxic Drug Targets for Multi Drug Resistant Mycobacterium tuberculosis.
Kaur D; Kutum R; Dash D; Brahmachari SK
Sci Rep; 2017 Apr; 7():46595. PubMed ID: 28425478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
